Phase 2 N=101 Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Hypothyroidism
Primary: Percentage of Participants That Do Not Need a Change of Dose — 32.9 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=64 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Adrenal Insufficiency
Primary: Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A — 3962.0; 4879.6 hour*nanomole…
N/A N=266 Evaluation of Approved Pacing Lead (Model 5076) for Use in MRI Environment
Magnetic Resonance Imaging (MRI) · Cardiac Pacing
Primary: MRI-related Complication Free Rate — 156 participants — p=<0.0001
Phase 2 N=18 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size · Iris Melanoma
Primary: Number of Participants With Response — 0; 0; 8; 9 participants
Phase 4 N=32 Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
Normal Tension Glaucoma · Ocular Hypertension
Primary: Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12 — 16.55; -3.37 mmHg
N/A N=79 A Comparison of Cognitive Processing Therapy (CPT) Versus Present Centered Therapy (PCT) for Veterans
PTSD
Primary: Clinician Administered PTSD Scale — 31.56; 42.62; 31.65; 38.73 units on a scale
N/A N=21 Blue Light for Treating Eczema
Eczema
Primary: Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Compared to the Control Area at End of Treatment — -1.9; -1.3 units on a…
N/A N=573 A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 52.431; 7.774 Approximate EDTRS Letters
Phase 2 N=11 Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
Colon Cancer · Colorectal Cancer · Gastrointestinal Cancer
Primary: Part 1: Number of Participants With Dose-limiting Toxicities (DLT) — 0 participants
Phase 4 N=79 Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline of Trough FEV1 at 12 Weeks on Study Drug. — 0.124; 0.186 Litres
Early Phase 1 N=11 Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis
Hemiparesis
Primary: Adverse Events/Safety Assessment. — 0; 0; 0; 0 Participants
Phase 2 N=32 The Effects of Decreasing the Lasix Dose on the Cardiorenal System
Heart Failure · Kidney Dysfunction
Primary: Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose — 77; 42; 73; 50 ml/min — p=<0.05
Phase 4 N=60 Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
Ischemic Stroke
Primary: Revascularization Status — 92 percentage of subjects TICI 2 or >
Phase 2 N=32 PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
Colonic Neoplasms
Primary: Concentration of [6R]-5,10-methylene-THF in Tumor Tissue — 1871; 959; 4725; 2393 pmol/g — p=0.0323
Phase 3 N=77 A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Change From Week 12 (Randomization) to Week 24 in DAS28 — 0.17; -0.16 score on a scale — p=0.188